IS5460A - 1´-[4-[1-(4-flúorófenýl)-1H-indól-3-ýl]-1-bútýl]-spíró [ísóbensófúran-1 (3H), 4´-píperídín]hýdrohalógeníð - Google Patents

1´-[4-[1-(4-flúorófenýl)-1H-indól-3-ýl]-1-bútýl]-spíró [ísóbensófúran-1 (3H), 4´-píperídín]hýdrohalógeníð

Info

Publication number
IS5460A
IS5460A IS5460A IS5460A IS5460A IS 5460 A IS5460 A IS 5460A IS 5460 A IS5460 A IS 5460A IS 5460 A IS5460 A IS 5460A IS 5460 A IS5460 A IS 5460A
Authority
IS
Iceland
Prior art keywords
hydrohalogenide
isobenzofuran
indol
spiro
fluorophenyl
Prior art date
Application number
IS5460A
Other languages
English (en)
Other versions
IS2342B (is
Inventor
Mørk Niels
Lopez De Diego Heidi
Nielsen Ole
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of IS5460A publication Critical patent/IS5460A/is
Publication of IS2342B publication Critical patent/IS2342B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS5460A 1997-11-07 2000-04-18 1´-[4-[1-(4-flúorófenýl)-1H-indól-3-ýl]-1-bútýl]-spíró [ísóbensófúran-1 (3H), 4´-píperídín]hýdrohalógeníð IS2342B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK126797 1997-11-07
PCT/DK1998/000480 WO1999024436A1 (en) 1997-11-07 1998-11-06 1'-[4-[1- (4-fluorophenyl)- 1h-indole-3-yl] -1-butyl]-spiro [isobenzofuran- 1(3h),4'- piperidine] hydrohalogenides

Publications (2)

Publication Number Publication Date
IS5460A true IS5460A (is) 2000-04-18
IS2342B IS2342B (is) 2008-02-15

Family

ID=8102935

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5460A IS2342B (is) 1997-11-07 2000-04-18 1´-[4-[1-(4-flúorófenýl)-1H-indól-3-ýl]-1-bútýl]-spíró [ísóbensófúran-1 (3H), 4´-píperídín]hýdrohalógeníð

Country Status (38)

Country Link
US (2) US6844352B2 (is)
EP (1) EP1044202B1 (is)
JP (1) JP3605358B2 (is)
KR (1) KR100399274B1 (is)
CN (1) CN1105115C (is)
AR (1) AR023010A1 (is)
AT (1) ATE288918T1 (is)
AU (1) AU749094B2 (is)
BG (1) BG64906B1 (is)
BR (1) BR9813949A (is)
CA (1) CA2308745C (is)
CZ (1) CZ288666B6 (is)
DE (1) DE69828999T2 (is)
DZ (1) DZ2642A1 (is)
EA (1) EA002092B1 (is)
EG (1) EG23791A (is)
ES (1) ES2234162T3 (is)
HR (1) HRP20000261B1 (is)
HU (1) HUP0100991A3 (is)
ID (1) ID25776A (is)
IL (1) IL135723A (is)
IS (1) IS2342B (is)
JO (1) JO2052B1 (is)
MA (1) MA25585A1 (is)
NO (1) NO325920B1 (is)
NZ (1) NZ504065A (is)
PE (1) PE130299A1 (is)
PL (1) PL190538B1 (is)
PT (1) PT1044202E (is)
RS (1) RS49777B (is)
SK (1) SK285245B6 (is)
TN (1) TNSN98201A1 (is)
TR (1) TR200001267T2 (is)
TW (1) TW483894B (is)
UA (1) UA64769C2 (is)
UY (1) UY25236A1 (is)
WO (1) WO1999024436A1 (is)
ZA (1) ZA9810116B (is)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013789A1 (en) * 2000-08-15 2002-02-21 H. Lundbeck A/S Pharmaceutical composition containing 1'-[4-[1-(4-fluorophenyl)-1h-indole-3-yl] -1-butyl]-spiro[isobenzofuran-1(3h),4'-piperidine]
WO2004026855A1 (en) * 2002-09-20 2004-04-01 H. Lundbeck A/S Method for manufacture of dihydroisobenzofuran derivatives
EP1644026A4 (en) 2003-06-12 2007-10-24 Ms Science Corp SIGMA LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RECREATION
EP1913378A1 (de) * 2005-07-29 2008-04-23 Sigma-Aldrich Production GmbH Ionisierungsadditive enthaltende lc/ms-blends
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2009536667A (ja) * 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
AU2007292848A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5109002A (en) * 1989-09-08 1992-04-28 Du Pont Merck Pharmaceutical Company Antipsychotic 1-cycloalkylpiperidines
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
BG104485A (en) 2001-01-31
TNSN98201A1 (fr) 2005-03-15
US20030055074A1 (en) 2003-03-20
DE69828999D1 (de) 2005-03-17
CN1278823A (zh) 2001-01-03
CN1105115C (zh) 2003-04-09
DE69828999T2 (de) 2005-07-21
TR200001267T2 (tr) 2000-09-21
US6844352B2 (en) 2005-01-18
YU23500A (sh) 2003-12-31
NO20002188L (no) 2000-06-14
CA2308745C (en) 2004-01-20
NO20002188D0 (no) 2000-04-27
AU1022699A (en) 1999-05-31
PT1044202E (pt) 2005-04-29
EP1044202A1 (en) 2000-10-18
UA64769C2 (uk) 2004-03-15
BG64906B1 (bg) 2006-08-31
HRP20000261A2 (en) 2001-04-30
JO2052B1 (en) 1999-05-15
EP1044202B1 (en) 2005-02-09
HUP0100991A3 (en) 2003-03-28
JP2001522852A (ja) 2001-11-20
UY25236A1 (es) 2000-12-29
AR023010A1 (es) 2002-09-04
DZ2642A1 (fr) 2004-12-28
SK285245B6 (sk) 2006-09-07
CZ20001663A3 (cs) 2000-10-11
ZA9810116B (en) 1999-05-07
IL135723A (en) 2005-11-20
HUP0100991A2 (hu) 2001-09-28
EG23791A (en) 2007-08-13
MA25585A1 (fr) 2002-12-31
RS49777B (sr) 2008-06-05
ES2234162T3 (es) 2005-06-16
ID25776A (id) 2000-11-02
PL190538B1 (pl) 2005-12-30
KR100399274B1 (ko) 2003-09-26
HRP20000261B1 (en) 2009-04-30
JP3605358B2 (ja) 2004-12-22
PE130299A1 (es) 1999-12-16
IS2342B (is) 2008-02-15
TW483894B (en) 2002-04-21
NZ504065A (en) 2002-05-31
HK1034075A1 (en) 2001-10-12
IL135723A0 (en) 2001-05-20
CA2308745A1 (en) 1999-05-20
KR20010031791A (ko) 2001-04-16
WO1999024436A1 (en) 1999-05-20
PL340220A1 (en) 2001-01-15
BR9813949A (pt) 2000-09-26
CZ288666B6 (cs) 2001-08-15
SK6462000A3 (en) 2000-10-09
ATE288918T1 (de) 2005-02-15
NO325920B1 (no) 2008-08-18
EA200000502A1 (ru) 2000-10-30
US20050171135A1 (en) 2005-08-04
EA002092B1 (ru) 2001-12-24
AU749094B2 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
IS5460A (is) 1´-[4-[1-(4-flúorófenýl)-1H-indól-3-ýl]-1-bútýl]-spíró [ísóbensófúran-1 (3H), 4´-píperídín]hýdrohalógeníð
FR2739028B1 (fr) Dispositif d'encapsulation de cellules ameliore
DE69611404D1 (de) Tintenstrahldruckkopf
AU2054197A (en) Posterior stabilized/constrained reamer guide
GB9715698D0 (en) Portable light for adjusting circadisn rhythm
DE69635379D1 (de) Atm-drosselung
DE69601823D1 (de) Tintenstrahlkopf
EP0743054A3 (en) Tilt mechanism for incubator
FR2738490B1 (fr) Dispositif d'irradiation pivotant
EP0726627A3 (en) Laser device
KR950001197U (ko) 레이져빔 프린터의 급배지장치
DK1044202T3 (da) 1'-[4-[1-(4-Fluorphenyl)-1H-indol-3-yl]-1-butyl]-spiro[isobenzofuran-1(3H),4'-piperidin]hydrohalogenider
FR2778879B1 (fr) Dispositif de reglage d'appui-tete
HUP0101706A3 (en) Use of 1'-[4-[1-(4-fluorphenyl)-1h-indole-3-yl]-1-butyl]-spiro[isobenzo-furan-1(3h),4'-piperidine] for the preparation of pharmaceutical composition treating panic attacks
GB9817988D0 (en) Optical pulse amplifier
SI1044202T1 (en) 1'- 4- 1- (4-fluorophenyl)- 1h-indole-3-yl) -1-butyl)-spiro isobenzofuran- 1(3h),4'- piperidine) hydrohalogenides
EP0472735A4 (en) Discharge excitation excimer laser device
GB9501694D0 (en) Stepped tapered leader
AU2202099A (en) Mammalian circadian regulator (m-rigui2 (m-per2))
AU2001279607A1 (en) Pharmaceutical composition containing 1'-(4-(1-(4-fluorophenyl)-1h-indole-3-yl) -1-butyl)-spiro(isobenzofuran-1(3h),4'-piperidine)
KR960036616U (ko) 통장프린터의 급지장치
KR970045937U (ko) 브이씨알 헤드높이 조절장치
KR970009880U (ko) 높이 조절이 용이한 건축용 인서트
IT239174Y1 (it) Porta menu con finestrelle per stampe
KR970047133U (ko) 밧데리 방전량 조절기구